This engaging session which took place on Tuesday, July 23rd, provided attendees with valuable perspectives and the chance to connect with the follicular lymphoma community.
The webinar featured an esteemed panel, including Dr. Mitchell Smith, FLF’s Chief Medical Officer, and Professor Jessica Okosun, an FLF Scientific Advisor, who shared specialist insights. They were joined by Nicky Greenhalgh, Founder of the “Living with FL” Facebook group, and Simon Earle, FLF Super Supporter and Patient Advocate, who provided invaluable patient perspectives.
Open to everyone, the webinar was particularly beneficial for patients, families, and caregivers. It catered to those making treatment decisions and those who had not yet started treatment, offering a deeper understanding of clinical trials to empower and enhance their patient journey.
The highlights of the webinar included:
– Learning from expert clinicians in follicular lymphoma
– Gaining valuable insights into clinical trials
– Hearing inspiring patient stories
– Getting questions answered
– Connecting with the follicular lymphoma community
[Disclaimer: This video is intended for educational and disease awareness purposes only and the information presented and discussed does not constitute medical advice.]
Your input matters
We value your suggestions, feedback, and topic requests for future webinars. If there’s a specific aspect of follicular lymphoma you’d like us to cover, or any other input you’d like to share, please reach out to us. We are committed to continuously improving our webinars based on your needs and interests.Â
If you’re unsure about any of the terms and treatments discussed, please visit our glossary.
Dr Mitchell Smith – Chief Medical Officer, Follicular Lymphoma Foundation
Dr Mitchell Smith has an extensive educational background, having earned his Medical Degree and PhD from Case Western Reserve University School of Medicine in Cleveland, OH. He has also completed several residencies and fellowships, including a Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Centre in NY. Dr Smith’s career has also spanned many years and institutions, including serving as Director of the Lymphoma Program at Fox Chase Cancer Centre and Director of the Lymphoid Malignancy Program at the Cleveland Clinic.
Prof Jessica Okosun – Scientific Advisor, Follicular Lymphoma Foundation, Assistant Professor and Clinician Scientist, Barts Cancer Institute
Prof Okosun is a Consultant Haematologist at St Bartholomew’s Hospital, London UK specialising in lymphomas. Her research interests are focused on understanding how lymphomas initiate, diversify and evolve, particularly follicular lymphoma in a bid to define novel biomarkers and improve treatment. Jessica has been advising the FLF since February 2019.
Nicky Greenhalgh – Founder of Living with Follicular Lymphoma Facebook group
Nicky was diagnosed with Stage 4, Grade 2, Follicular Non-Hodgkins Lymphoma in 2014 when she was just 32 years old. She was immediately accepted into a clinical trial and has since been progression free for almost 10 years. Nicky is keen to share her experience being involved in a clinical trial to try and help others who may be faced with the option of a clinical trial.
Simon Earle –Â Follicular Lymphoma Foundation Super Supporter and Patient Advocate
Simon was diagnosed with diffuse large B cell lymphoma (DLBCL) in 1999 and underwent CHOP chemotherapy and intrathecal methotrexate. He also underwent Bendamustine and Rituximab in 2017 following a relapse when his lymphoma presented as follicular Lymphoma. After being diagnosed with heart failure (probably as a result of the chemotherapy) he took part in a clinical trial for stem cell treatment for his heart condition and also suffered a stroke in 2020. Simon is now retired and supports several charities as a patient advocate including the FLF.
Â
This webinar series is supported by an educational grant from Genmab US, Inc and AbbVie and sponsorship from BeiGene USA, Inc., Novartis and Kite Gilead. This Clinical Trials webinar has also been sponsored by Ipsen and BioInvent International AB. All of the above have had no influence on, control of, nor input into the development or performance of the webinar series.